Dynamic imaging of emerging resistance during cancer therapy

Cancer Research

Volumn 66, Issue 9, 2006, Pages 4687-4692

  Lee, Kuei C ^a   Hall, Daniel E ^a   Hoff, Benjamin A ^a   Moffat, Bradford A ^a   Sharma, Surabhi ^a   Chenevert, Thomas L ^a   Meyer, Charles R ^a   Leopold, Wilbur R ^b   Johnson, Timothy D ^a   Mazurchuk, Richard V ^c   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MIR Preclinical Services   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG DOSE REGIMEN; EX VIVO STUDY; GLIOMA; GROWTH INHIBITION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CARMUSTINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GLIOMA; MALE; RATS; RATS, INBRED F344;

EID: 33646411743     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3205     Document Type: Article

References (32)

1. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003;361:323-31.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
3. Dexter DL, Calabresi P. Intraneoplastic diversity. Biochim Biophys Acta 1982;695:97-112.
4. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:998-1003.
5. Heppner GH. Tumor cell societies. J Natl Cancer Inst 1989;81:648-9.
6. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-53.
7. Heros DO, Renkens K, Kasdon DL, et al. Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. Neurosurgery 1988;22:474-8.
8. Rudoler S, Corn BW, Werner-Wasik M, et al. Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era. Am J Clin Oncol 1998;21:23-7.
9. Ross BD, Chenevert TL, Kim B, et al. Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1994;1:89-106.
10. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000;43:828-36.
11. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60.
12. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
13. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457-66.
14. 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidinc kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 1998;58:3791-9.
15. Galons JP, Altbach MI, Paine-Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-7.
16. Stegman LD, Rehemtulla A, Hamstra DA, et al. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 2000;7:1005-10.
17. Hamstra DA, Lee KC, Tychewicz JM, et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004;10:916-28.
18. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic-efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10:7852-9.
19. Ross BD, Zhao YJ, Neal ER, et al. Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci U S A 1998;95: 7012-7.
20. Wong EC, Cox RW, Song AW. Optimized isotropic diffusion weighting. Magn Reson Med 1995;34:139-43.
21. Meyer CR, Boes JL, Kim B, et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1997;1:195-206.
22. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
23. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for early prediction of cancer treatment outcome. Neoplasia 2006;8:259-66.
24. Barker M, Hoshino T, Gurcay O, et al. Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 1973;33:976-86.
25. Chenevert TL, Meyer CR, Moffat BA, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1:336-43.
26. Poptani H, Puumalainen AM, Grohn OH, et al. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998;5:101-9.
27. 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996;73:61-4.
28. Evelhoch JL, Gillies RJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000;2:152-65.
29. Rowley HA, Grant PE, Roberts TP. Diffusion MR imaging. Theory and applications. Neuroimaging Clin N Am 1999;9:343-61.
30. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-9.
31. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102:16759-64.
32. Saito R, Bringas J, Mirek H, et al. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma. J Neurosurg 2004;101:826-31.